- Home
- AOMR vs PVLA Comparison
AOMR vs PVLA Comparison
Compare AOMR & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- PVLA
- Stock Information
- Founded
- AOMR 2018
- PVLA 2015
- Country
- AOMR United States
- PVLA United States
- Employees
- AOMR N/A
- PVLA N/A
- Industry
- AOMR Real Estate Investment Trusts
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- AOMR Real Estate
- PVLA Health Care
- Exchange
- AOMR Nasdaq
- PVLA Nasdaq
- Market Cap
- AOMR 237.8M
- PVLA 249.2M
- IPO Year
- AOMR 2021
- PVLA N/A
- Fundamental
- Price
- AOMR $9.66
- PVLA $25.92
- Analyst Decision
- AOMR Strong Buy
- PVLA Strong Buy
- Analyst Count
- AOMR 7
- PVLA 7
- Target Price
- AOMR $11.57
- PVLA $46.29
- AVG Volume (30 Days)
- AOMR 82.5K
- PVLA 129.2K
- Earning Date
- AOMR 08-05-2025
- PVLA 08-15-2025
- Dividend Yield
- AOMR 13.31%
- PVLA N/A
- EPS Growth
- AOMR N/A
- PVLA N/A
- EPS
- AOMR 1.51
- PVLA N/A
- Revenue
- AOMR $57,147,000.00
- PVLA N/A
- Revenue This Year
- AOMR N/A
- PVLA N/A
- Revenue Next Year
- AOMR $10.94
- PVLA N/A
- P/E Ratio
- AOMR $6.36
- PVLA N/A
- Revenue Growth
- AOMR N/A
- PVLA N/A
- 52 Week Low
- AOMR $7.36
- PVLA $11.17
- 52 Week High
- AOMR $12.94
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- AOMR 62.26
- PVLA N/A
- Support Level
- AOMR $9.54
- PVLA N/A
- Resistance Level
- AOMR $9.75
- PVLA N/A
- Average True Range (ATR)
- AOMR 0.15
- PVLA 0.00
- MACD
- AOMR 0.05
- PVLA 0.00
- Stochastic Oscillator
- AOMR 75.31
- PVLA 0.00
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.